Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Novel Imaging diagnostics and treatment modalities for clear cell kidney cancer

Reference number
Funding from Vinnova SEK 500 000
Project duration July 2017 - August 2018
Status Completed

Purpose and goal

The purpose of this project was to develop a new specific diagnostic method for detecting clear cell kidney cancer based on an already existing method of detecting the biomarker DAT. We therefore initiated a clinical trial for the evaluation of the existing diagnostic drug. In this trial we have analyzed five patients with suspected metastatic renal cancer and have thereafter assessed the diagnostic method.

Expected results and effects

The results from the trial showed that the existing method was not adequate to be used for detection of kidney tumors as it is today. We believe that DAT detection can be used to identify clear cell kidney cancer tumors, but increased sensitivity and specificity compared to the current method is required. New molecules for DAT detection have been identified and the business plan has thus been updated and improved. In the project process, Key Opinion Leaders have been identified and valuable contacts have been established

Planned approach and implementation

Akuru Pharma has worked as a coordinating party in this project and has coordinated interaction between the monitor, clinic and creator of CRF. The trial has been conducted in collaboration with Lund University and Region Skåne. Region Skåne has been responsible for the patient recruitment and the scan. Analysis of the results has been performed by independent radiologist. The coordinator has executed all communication with relevant authorities such as the MPA, ethical vetting board and radiation protection authorities.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2017-03367

Page statistics